Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports.Check Now!
ERS 2025 Top Abstracts: Redefining the Future of Respiratory Care with Next-Generation Therapies
- Home
- ERS Conference
- top 10 abstracts at ers 2025
Top 10+ Must-See Abstracts at ERS 2025
Chronic respiratory diseases (CRDs) remain both underestimated and underprioritized in Europe, despite new data showing they affect nearly 82 million people and drive USD 21 billion in annual costs. The recently released WHO/ European Respiratory Society (ERS) report highlights how systemic failures—ranging from weak primary care diagnostics to inadequate policy focus—have obscured the true magnitude of asthma, COPD, and rarer lung diseases.
What stands out in the ERS 2025 respiratory trial landscape is a clear bifurcation of innovation between consolidation and disruption. On one side, established leaders like GSK and Sanofi/Regeneron are fortifying their dominance: GSK’s depemokimab headlines multiple Phase III abstracts (SWIFT-1/2, ANCHOR-1/2), positioning a twice-yearly IL-5 antibody as the next inflection point in asthma and CRSwNP, while NUCALA (Mepolizumab) makes its strongest bid yet in COPD with pooled data and long-term analyses from METREX, METREO, and MATINEE. Sanofi/Regeneron, meanwhile, leverage DUPIXENT’s (dupilumab) multi-disease brand equity, presenting COPD data across cardiovascular, metabolic, and elderly subgroups, reinforcing its real-world versatility. Together, these programs highlight how market incumbents are using life-cycle strategies to expand dominance beyond asthma into COPD and comorbidity-driven niches.
On the other side, emerging biotechs and novel mechanisms are intensifying competitive pressure, particularly in COPD, fibrosis, and bronchiectasis—areas where underdiagnosis and lack of targeted therapies have left major gaps. Novel entrants like astelolimab (ST2), TQC3721 (dual PDE3/4 inhibitor), and amlitelimab (OX40-L blockade) reflect a diversification of immunological targets, while bispecific constructs (BBT002, ZW1528) point to an oncology-style arms race for pathway coverage. Meanwhile, fibrosis and bronchiectasis are stepping into the spotlight with MTX-463 (WISP inhibitor), PMG1015, and BI 1291583 (Cathepsin C/DPP1 inhibitor), opening fresh growth corridors beyond traditional asthma-COPD markets. The pipeline breadth signals a pivot from incremental improvements toward true mechanistic disruption—aligning with WHO’s call for research and innovation to address the neglected CRD burden.
Taken together, the ERS 2025 abstract lineup underscores a dual dynamic: established blockbusters are being redefined through life-cycle innovation, while emerging assets are reshaping competitive frontiers in COPD, fibrosis, and bronchiectasis. The following table highlights 10+ most impactful abstracts that capture this evolving respiratory R&D and market narrative.
|
Company |
Drug and Target |
Indication |
Trial ID / Acronym |
Phase |
Abstract ID |
Abstract Title |
|
GSK |
Depemokimab (IL-5) | Asthma |
NCT04718103 (SWIFT-2), NCT04719832 (SWIFT-1) |
Phase III |
PA2469 |
Twice-yearly depemokimab demonstrates efficacy in patients with asthma across baseline medium- and high-dose ICS subgroups: Phase III SWIFT-1/2 studies |
|
PA2478 |
Clinical remission in patients with asthma treated with twice-yearly depemokimab in the Phase III SWIFT-1/2 studies | |||||
|
PA2488 |
Twice-yearly depemokimab reduces exacerbations versus placebo in patients with asthma across age of onset/duration subgroups: Phase III SWIFT-1/2 studies | |||||
|
Asthma with Comorbid chronic rhinosinusitis with nasal polyps (CRSwNP) |
NCT04718103 (SWIFT-2), NCT04719832 (SWIFT-1) |
Phase III |
OA2334 |
Twice-yearly depemokimab demonstrates efficacy in patients with asthma and comorbid chronic rhinosinusitis with nasal polyps (CRSwNP): Phase III SWIFT-1/2 studies | ||
|
Comorbid chronic rhinosinusitis with nasal polyps (CRSwNP) |
NCT05274750 (ANCHOR-1), NCT05281523 (ANCHOE-2) |
Phase III |
OA2335 |
Depemokimab is associated with early and sustained improvements in patient-reported outcomes in CRSwNP: Data from the ANCHOR-1/2 trials | ||
|
GSK |
NUCALA (mepolizumab) (IL-5) |
COPD |
NCT02105948 (METREX), NCT02105961 (METREO), NCT04133909 (MATINEE) |
Phase III |
PA4585 |
Efficacy of mepolizumab in patients with COPD & type 2 inflammation: Pooled Phase III trial results |
|
PA486 |
Mepolizumab is efficacious in COPD patients with varying levels of airflow obstruction: Pooled Phase III trial results | |||||
|
PA487 |
Mepolizumab reduces exacerbations and improves quality of life in COPD irrespective of severe exacerbation | |||||
|
COPD |
NCT04133909 (MATINEE) |
Phase III |
[LBA] OA6519 |
Sustained FEV1 improvements with mepolizumab up to 104 weeks in patients with COPD and less severe airflow obstruction: Post hoc analysis of the MATINEE Phase III study | ||
|
Mabwell |
9MW1911 (ST2) |
COPD |
NCT05170243 |
Phase I |
PA2475 |
First-in-human study of 9MW1911 (an anti-ST2 monoclonal antibody) in healthy volunteers |
|
Forsee Pharmaceuticals |
Linvemastat (MMP12) |
Asthma |
NA |
Phase II |
PA2473 |
A Multinational Phase 2, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Effect of Linvemastat (MMP12 inhibitor) in Patients with Uncontrolled Asthma on Inhaled Corticosteroids (ICS) with LongActing Beta Agonist (LABA) as SOC |
|
Zymeworks |
ZW1528 (IL-4Rα and IL-33) |
COPD |
NA |
Preclinical |
[LBA] PA4587 |
ZW1528: A dual-targeting bispecific antibody to broadly suppress airway inflammation by inhibiting IL-4Ra and IL 33 pathways |
|
Roche/Amgen
|
Astegolimab (IL-33 through ST2 receptor) |
COPD |
NCT05595642 (ARNASA) |
Phase III |
PA6023 |
ARNASA: A Phase III randomised, double-blind, placebo controlled trial of astegolimab for COPD with frequent exacerbations |
|
NCT05037929 (ALIENTO) |
Phase II |
RCT1116 |
Randomised, placebo-controlled trial of astegolimab for COPD with frequent exacerbations: ALIENTO | |||
|
Mediar Therapeutics/Eli Lilly |
MTX-463 (WISP-1) |
Idiopathic pulmonary fibrosis (IPF) |
NCT06401213 |
Phase I |
[LBA] PA1031 |
A Phase I trial to evaluate the safety, PK and target engagement of MTX-463, a monoclonal antibody inhibitor of WISP |
|
Sanofi |
Amlitelimab (OX40 ligand) |
Asthma |
NCT05421598 |
Phase II |
[LBA] OA1180 |
Amlitelimab phase 2 clinical trial results in patients with moderate-to-severe asthma |
|
Pulmongene |
PMG1015 (AREG) |
IPF |
NCT05895565 |
Phase Ib |
[LBA] PA6092 |
PMG1015 demonstrates well-tolerated safety and favorable FVC changes after 12 weeks of treatment in IPF Patients |
|
Boehringer Ingelheim |
Verducatib/BI 1291583 (Cathepsin C) |
Bronchiectasis |
NCT05238675 (AIRLEAF), NCT05846230 (CLAIRLEAF) |
Phase II |
PA4960 |
Pooled data from Phase II studies (AIRLEAF, CLAIRLEAF) of the cathepsin C (CatC, or DPP1) inhibitor BI 1291583 in bronchiectasis |
|
Non–cystic fibrosis bronchiectasis |
NCT05238675 (AIRLEAF) |
Phase II |
PA4959 |
Subgroup analysis: AIRLEAF Phase II study of a cathepsin C (CatC, or DPP1) inhibitor, BI 1291583, in adults with non–cystic fibrosis bronchiectasis | ||
|
Bambusa/Biotheus
|
BBT002 (IL-4α and IL-5) |
COPD |
NA |
Preclinical |
OA6528 |
BBT002, a tetravalent bispecific antibody targeting human IL-4Rα and IL-5, demonstrated synergistic efficacy in |
|
Generate:Biomedicines |
GB-0895 (TSLP) |
Asthma |
NA |
Preclinical |
[LBA] OA2332 |
GB-0895, a high-affinity anti-TSLP mAb, demonstrates prolonged half-life and sustained pharmacological activity supporting every 6-month dosing in asthma |
|
Chia Tai Tianqing Pharmaceutical |
TQC3721 (Phosphodiesterase 3 and 4) |
COPD |
NCT06527144 |
Phase II |
[LBA] PA4595 |
Effects of a Novel Dual Phosphodiesterase 3 and 4 Inhibitor TQC3721 in Patients with COPD in China (PACER II): a Phase II, multicentre, randomised, double-blind, placebo-controlled trial |
|
Sanofi/Regeneron
|
DUPIXENT (dupilumab) (IL-4/IL-13) |
COPD |
NCT03930732 (BOREAS), NCT04456673 (NOTUS) |
Phase III |
PA4573 |
Association between dupilumab and repeated exacerbations of COPD: BOREAS and NOTUS |
|
PA4575 |
Dupilumab efficacy in patients with COPD and cardiovascular or metabolic disease: | |||||
|
PA4576 |
Effect of add-on dupilumab in elderly patients with chronic obstructive pulmonary disease: BOREAS and NOTUS | |||||
|
Asthma |
NCT04998604 (EVEREST) |
Phase IV |
RCT1114 |
Efficacy and Safety of Dupilumab (DUP) vs Omalizumab (OMA) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) with Asthma (EVEREST study) |
Executive Summary
Chronic respiratory diseases (CRDs) remain both underestimated and underprioritized in Europe, despite new data showing they affect nearly 82 million people and drive USD 21 billion in annual costs.